Temple publishes BrainFlow validation research ahead of planned India launch
Deepinder Goyal’s Temple has released a preprint study claiming its BrainFlow wearable tracks brain blood-volume changes more closely than scalp signals. The company is preparing pre-orders, with limited-edition shipments potentially starting before end-2026; no India launch date is confirmed.
What happened
Deepinder Goyal’s Temple released a preprint validation study for its BrainFlow wearable ahead of an India launch. The company says the device tracks brain
Key facts
- 44 healthy participants
- 60 sessions
- 30-degree head-down tilt
- BrainFlow-brain signal correlation: 0.912
- BrainFlow-scalp signal correlation: 0.494
Why this matters
Temple’s attempt to validate a distinct brain blood-volume signal could make it a partnership or acquisition watchlist candidate for health-tech players, pending peer-reviewed evidence and launch traction.
What to watch
- Whether the preprint receives peer review, independent replication or substantive methodological criticism.
- Exact BrainFlow use cases, pricing, subscription requirements and battery/form-factor details.
- Pre-order timing, deposit volume, stated shipping schedule and evidence of manufacturing readiness.
- Whether Temple markets wellness insights versus medical, neurological or diagnostic outcomes.
- Any CDSCO, consumer-protection or advertising-compliance discussion tied to the device's claims.
- Partnerships with hospitals, research institutions, sleep clinics, insurers or corporate-wellness buyers.
- Early-user retention, repeat app engagement and accuracy feedback after limited-edition shipments.
- Open a waitlist or limited-edition pre-order program with refundable deposits and phased shipment windows.
- Release fuller methodology, comparison data and expert commentary to convert a preprint into commercial credibility.
- Define permitted consumer claims around focus, stress, recovery or sleep while avoiding diagnostic language.
- Build a clinical-advisory network and pursue additional India-based validation cohorts.
- Use Goyal's audience and selective creator demos to seed demand, then tightly control early-unit supply.